De novo discovery of serotonin N-acetyltransferase inhibitors

Lawrence M. Szewczuk, S. Adrian Saldanha, Surajit Ganguly, Erin M. Bowers, Margarita Javoroncov, Balasubramanyam Karanam, Jeffrey C. Culhane, Marc A. Holbert, David C. Klein, Ruben Abagyan, Philip A. Cole

Research output: Contribution to journalArticle

Abstract

Serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase, AANAT) is a member of the GCN5 N-acetyltransferase (GNAT) superfamily and catalyzes the penultimate step in the biosynthesis of melatonin; a large daily rhythm in AANAT activity drives the daily rhythm in circulating melatonin. We have used a structure-based computational approach to identify the first druglike and selective inhibitors of AANAT. Approximately 1.2 million compounds were virtually screened by 3D high-throughput docking into the active site of X-ray structures for AANAT, and in total 241 compounds were tested as inhibitors. One compound class, containing a rhodanine scaffold, exhibited low micromolar competitive inhibition against acetyl-CoA (AcCoA) and proved to be effective in blocking melatonin production in pineal cells. Compounds from this class are predicted to bind as bisubstrate inhibitors through interactions with the AcCoA and serotonin binding sites. Overall, this study demonstrates the feasibility of using virtual screening to identify small molecules that are selective inhibitors of AANAT.

Original languageEnglish (US)
Pages (from-to)5330-5338
Number of pages9
JournalJournal of Medicinal Chemistry
Volume50
Issue number22
DOIs
StatePublished - Nov 1 2007

Fingerprint

Arylalkylamine N-Acetyltransferase
Melatonin
Acetyl Coenzyme A
Rhodanine
Acetyltransferases
Biosynthesis
Feasibility Studies
Scaffolds
Catalytic Domain
Serotonin
Screening
Binding Sites
Throughput
X-Rays
X rays
Molecules

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Szewczuk, L. M., Saldanha, S. A., Ganguly, S., Bowers, E. M., Javoroncov, M., Karanam, B., ... Cole, P. A. (2007). De novo discovery of serotonin N-acetyltransferase inhibitors. Journal of Medicinal Chemistry, 50(22), 5330-5338. https://doi.org/10.1021/jm0706463

De novo discovery of serotonin N-acetyltransferase inhibitors. / Szewczuk, Lawrence M.; Saldanha, S. Adrian; Ganguly, Surajit; Bowers, Erin M.; Javoroncov, Margarita; Karanam, Balasubramanyam; Culhane, Jeffrey C.; Holbert, Marc A.; Klein, David C.; Abagyan, Ruben; Cole, Philip A.

In: Journal of Medicinal Chemistry, Vol. 50, No. 22, 01.11.2007, p. 5330-5338.

Research output: Contribution to journalArticle

Szewczuk, LM, Saldanha, SA, Ganguly, S, Bowers, EM, Javoroncov, M, Karanam, B, Culhane, JC, Holbert, MA, Klein, DC, Abagyan, R & Cole, PA 2007, 'De novo discovery of serotonin N-acetyltransferase inhibitors', Journal of Medicinal Chemistry, vol. 50, no. 22, pp. 5330-5338. https://doi.org/10.1021/jm0706463
Szewczuk LM, Saldanha SA, Ganguly S, Bowers EM, Javoroncov M, Karanam B et al. De novo discovery of serotonin N-acetyltransferase inhibitors. Journal of Medicinal Chemistry. 2007 Nov 1;50(22):5330-5338. https://doi.org/10.1021/jm0706463
Szewczuk, Lawrence M. ; Saldanha, S. Adrian ; Ganguly, Surajit ; Bowers, Erin M. ; Javoroncov, Margarita ; Karanam, Balasubramanyam ; Culhane, Jeffrey C. ; Holbert, Marc A. ; Klein, David C. ; Abagyan, Ruben ; Cole, Philip A. / De novo discovery of serotonin N-acetyltransferase inhibitors. In: Journal of Medicinal Chemistry. 2007 ; Vol. 50, No. 22. pp. 5330-5338.
@article{5912cd4eb83e481eb8a3948ce53d4ff3,
title = "De novo discovery of serotonin N-acetyltransferase inhibitors",
abstract = "Serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase, AANAT) is a member of the GCN5 N-acetyltransferase (GNAT) superfamily and catalyzes the penultimate step in the biosynthesis of melatonin; a large daily rhythm in AANAT activity drives the daily rhythm in circulating melatonin. We have used a structure-based computational approach to identify the first druglike and selective inhibitors of AANAT. Approximately 1.2 million compounds were virtually screened by 3D high-throughput docking into the active site of X-ray structures for AANAT, and in total 241 compounds were tested as inhibitors. One compound class, containing a rhodanine scaffold, exhibited low micromolar competitive inhibition against acetyl-CoA (AcCoA) and proved to be effective in blocking melatonin production in pineal cells. Compounds from this class are predicted to bind as bisubstrate inhibitors through interactions with the AcCoA and serotonin binding sites. Overall, this study demonstrates the feasibility of using virtual screening to identify small molecules that are selective inhibitors of AANAT.",
author = "Szewczuk, {Lawrence M.} and Saldanha, {S. Adrian} and Surajit Ganguly and Bowers, {Erin M.} and Margarita Javoroncov and Balasubramanyam Karanam and Culhane, {Jeffrey C.} and Holbert, {Marc A.} and Klein, {David C.} and Ruben Abagyan and Cole, {Philip A.}",
year = "2007",
month = "11",
day = "1",
doi = "10.1021/jm0706463",
language = "English (US)",
volume = "50",
pages = "5330--5338",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "22",

}

TY - JOUR

T1 - De novo discovery of serotonin N-acetyltransferase inhibitors

AU - Szewczuk, Lawrence M.

AU - Saldanha, S. Adrian

AU - Ganguly, Surajit

AU - Bowers, Erin M.

AU - Javoroncov, Margarita

AU - Karanam, Balasubramanyam

AU - Culhane, Jeffrey C.

AU - Holbert, Marc A.

AU - Klein, David C.

AU - Abagyan, Ruben

AU - Cole, Philip A.

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase, AANAT) is a member of the GCN5 N-acetyltransferase (GNAT) superfamily and catalyzes the penultimate step in the biosynthesis of melatonin; a large daily rhythm in AANAT activity drives the daily rhythm in circulating melatonin. We have used a structure-based computational approach to identify the first druglike and selective inhibitors of AANAT. Approximately 1.2 million compounds were virtually screened by 3D high-throughput docking into the active site of X-ray structures for AANAT, and in total 241 compounds were tested as inhibitors. One compound class, containing a rhodanine scaffold, exhibited low micromolar competitive inhibition against acetyl-CoA (AcCoA) and proved to be effective in blocking melatonin production in pineal cells. Compounds from this class are predicted to bind as bisubstrate inhibitors through interactions with the AcCoA and serotonin binding sites. Overall, this study demonstrates the feasibility of using virtual screening to identify small molecules that are selective inhibitors of AANAT.

AB - Serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase, AANAT) is a member of the GCN5 N-acetyltransferase (GNAT) superfamily and catalyzes the penultimate step in the biosynthesis of melatonin; a large daily rhythm in AANAT activity drives the daily rhythm in circulating melatonin. We have used a structure-based computational approach to identify the first druglike and selective inhibitors of AANAT. Approximately 1.2 million compounds were virtually screened by 3D high-throughput docking into the active site of X-ray structures for AANAT, and in total 241 compounds were tested as inhibitors. One compound class, containing a rhodanine scaffold, exhibited low micromolar competitive inhibition against acetyl-CoA (AcCoA) and proved to be effective in blocking melatonin production in pineal cells. Compounds from this class are predicted to bind as bisubstrate inhibitors through interactions with the AcCoA and serotonin binding sites. Overall, this study demonstrates the feasibility of using virtual screening to identify small molecules that are selective inhibitors of AANAT.

UR - http://www.scopus.com/inward/record.url?scp=35848944141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35848944141&partnerID=8YFLogxK

U2 - 10.1021/jm0706463

DO - 10.1021/jm0706463

M3 - Article

C2 - 17924613

AN - SCOPUS:35848944141

VL - 50

SP - 5330

EP - 5338

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 22

ER -